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BACKGROUND: Overexpression of ErbB2 receptor in breast cancer is associated with disease progression and poor prognosis.
Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer, has proven to be effective; however, a relevant
problem for clinical practice is that a high fraction of breast cancer patients shows primary or acquired resistance to trastuzumab
treatment.
METHODS: We tested on trastuzumab-resistant cells two novel human anti-tumour immunoconjugates engineered in our laboratory
by fusion of a human anti-ErbB2 scFv, termed Erbicin, with either a human RNase or the Fc region of a human IgG1. Both Erbicin-
derived immunoagents (EDIAs) are selectively cytotoxic for ErbB2-positive cancer cells in vitro and vivo, target an ErbB2 epitope
different from that recognised by trastuzumab and do not show cardiotoxic effects.
RESULTS: We report that EDIAs are active also on trastuzumab-resistant tumour cells both in vitro and in vivo, most likely because
of the different epitope recognised, as EDIAs, unlike trastuzumab, were found to be able to inhibit the signalling pathway downstream
of ErbB2.
CONCLUSION: These results suggest that EDIAs are immunoagents that could not only fulfil the therapeutic need of patients ineligible
to trastuzumab treatment due to cardiac dysfunction but also prove to be useful for breast cancer patients unresponsive to
trastuzumab treatment.
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Breast cancer is a disease with more than one million new
diagnoses worldwide each year and with a high risk of metastases.
Several studies have shown that up to 25% of breast cancers
overexpress a member of the HER/ErbB transmembrane receptor
tyrosine kinase family, ErbB2, associated with poor prognosis and
with a more aggressive clinical behaviour (Baselga and Albanell,
2001). Overexpression of ErbB2 leads to activation of the ErbB2-
mediated signalling pathways, including the mitogen-activated
protein kinase (MAPK) and phosphatidylinositol-3-kinase path-
ways. The first ErbB2-targeted therapy approved by the United
States Food and Drug Administration is trastuzumab, a humanised
monoclonal antibody that binds to the extracellular domain of
HER2. Trastuzumab development has led to a significant
improvement in the outcomes of patients with ErbB2-positive
breast cancer. It has been reported that trastuzumab induces
internalisation and downregulation of ErbB2 (Sliwkowski et al,
1999), cell cycle arrest (Baselga and Albanell, 2001; Kim et al,
2003), inhibition of angiogenesis (Izumi et al, 2002) and induction
of antibody-dependent cell-mediated cytotoxicity (ADCC) (Clynes
et al, 2000). Several studies showed that the use of trastuzumab
alone in first-line metastatic breast cancer resulted in a median
overall response rate of 19–26% (Vogel et al, 2002). Moreover, in
the first-line setting, the use of trastuzumab in combination with
chemotherapy results in a longer time to disease progression, a
higher rate of objective response, a longer duration of response
and a 20% reduction in the risk of death (Slamon et al, 2001).
However, many patients with HER2-positive metastatic breast
cancer do not respond to trastuzumab, or eventually become
resistant to it. For these patients, the prognosis is poor and the
disease progresses more aggressively. Resistance to trastuzumab is
often associated with an increased expression of the membrane-
associated glycoprotein mucin-4 (MUC4), which binds and
sterically hinders ErbB2 from binding to trastuzumab. Further-
more, MUC4 can also activate the receptor through its epidermal
growth factor (EGF)-like domain (Nagy et al, 2005).
The JIMT-1 cell line was isolated from a pleural effusion in a
patient with metastatic ErbB2-driven breast disease who was
clinically resistant to trastuzumab therapy. This cell line shows
her2/ErbB2 gene amplification and an elevated MUC4 expression
level, which masks the trastuzumab-binding epitopes of ErbB2
(Tanner et al, 2004). The KPL-4 cell line was isolated from the
malignant pleural effusion of a breast cancer patient with an
inflammatory skin metastasis; in female athymic nude mice, KPL-4
cells are mostly resistant to trastuzumab (Kurebayashi et al, 1999).
Two novel human anti-ErbB2 immunoconjugates have been
engineered in our laboratory by fusion of a human scFv
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s(De Lorenzo et al, 2002), termed Erbicin, with either a human
RNase or the Fc region of a human IgG1. The former is called
Erb-hRNase, the latter human anti-ErbB2-compact Antibody
(Erb-hcAb). Both immunoagents are selectively cytotoxic for
ErbB2-positive cancer cells in vitro and in vivo (De Lorenzo
et al, 2004a,b, 2005).
These Erbicin-derived immunoagents (EDIAs) target an ErbB2
epitope on breast cancer cells different from that of trastuzumab
(De Lorenzo et al, 2007a). Previous reports have suggested that the
epitope recognised by trastuzumab may be masked in trastuzu-
mab-resistant tumour cells (Nagy et al, 2005; Valabrega et al,
2007), given that they could still be sensitive to treatment with
antibodies recognising different epitopes. Thus, the use of EDIAs,
which recognise a different site on ErbB2, could prove to be
effective for treatment of breast cancer that cannot be cured with
trastuzumab.
In this study, we evaluated whether our agents are effective also
in cancer cell lines with spontaneous or acquired resistance to
trastuzumab, in vitro and in vivo.
MATERIALS AND METHODS
Cell cultures
The KPL-4 cell line was isolated from the malignant pleural
effusion of a breast cancer patient with an inflammatory skin
metastasis; in female athymic nude mice, KPL-4 cells are mostly
resistant to trastuzumab (Kurebayashi et al, 1999). The JIMT-1 cell
line was established from a pleural metastasis of a 62-year-old
patient with breast cancer who was clinically resistant to
trastuzumab, and forms trastuzumab-resistant xenografts in nude
mice (Tanner et al, 2004). KPL-4, JIMT-1 and MDA-MB 361 breast
cancer cells were maintained in RPMI medium supplemented with
10% heat-inactivated foetal bovine serum, 20mM HEPES, pH 7.4,
penicillin (100UIml
1), streptomycin (100mgml
1) and 4mM
glutamine (ICN, Irvine, UK) in a humidified atmosphere of 95%
air and 5% CO2 at 371C.
Compounds
The antibodies used were trastuzumab (Genentech, South San
Francisco, CA, USA), horseradish peroxidase-conjugated goat anti-
human affinity-isolated IgG1 (Fc-specific; Sigma, St Louis, MO,
USA), Erb-hcAb and Erb-hRNase. These latter were prepared as
described previously (De Lorenzo et al, 2004a,b).
Western blot analysis
Total cell lysates were obtained from cellular lysates or homo-
genised tumour specimens removed on day 25. Protein extracts
were resolved by 4–15% SDS–polyacrylamide gel electrophoresis
and probed with anti-human, monoclonal pEGFR, polyclonal
EGFR, polyclonal pHER2, monoclonal HER2, monoclonal pMAPK
and monoclonal MAPK, monoclonal vascular endothelial growth
factor (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mono-
clonal pAkt, polyclonal Akt (Cell Signaling Technologies, Beverly,
MA, USA) and monoclonal actin (Sigma-Aldrich, Milan, Italy).
Immunoreactive proteins were visualised by enhanced chemilu-
minescence (Pierce, Rockford, IL, USA), as previously described
(Ciardiello et al, 2004).
Growth in soft agar
On day 0, cells were suspended in 0.3% Difco Noble agar (Difco,
Detroit, MI, USA) supplemented with complete culture medium,
layered over 0.5ml of 0.8% agar medium base and treated with
different nM concentrations of Erb-hRNase and Erb-hcAb alone.
After 10–14 days, cells were stained with nitro blue tetrazolium
(Sigma Chemical Co., Milan, Italy) and colonies 40.05mm were
counted (Ciardiello et al,2 0 0 4 ) .T y p i c a l l y ,s . d .v a l u e sw e r eb e l o w1 0 % .
In vitro assay of drug sensitivity in the absence of serum
To test the effects of EDIA on the growth of JIMT-1 and KPL-4 cell
lines, cells were plated at a density of 5000 cells per well in 96-well,
flat-bottomed, tissue culture plates deprived of serum for the
following 24h and then treated with immunoagents (50–200nM)
for 72h, as previously reported (Tanner et al, 2004). Cell counts
were determined in triplicate using the trypan blue exclusion test
and survival was expressed as percentage of viable treated cells
with respect to control untreated cultures. Typically, s.d. values
were below 10%.
Xenografts in nude mice
Balb/cAnNCrlBR athymic (nu/nu) mice (5 weeks old) (Charles
River Laboratories, Milan, Italy) were maintained in accordance
with the institutional guidelines of the University of Naples Animal
Care Committee and in accordance with the Declaration of
Helsinki and the Italian regulations for the welfare of animals
used in studies of experimental neoplasia. The study was approved
by the School of Medicine Institutional Committee on animal care.
KPL-4 or JIMT-1 human breast cancer cells (10
7 cells per mice)
were resuspended in 200ml of Matrigel (Collaborative Biomedical
Products, Bedford, MA, USA) and injected subcutaneously into
mice. After 7 days, tumours were detected and groups of 10 mice
were randomised to receive the following treatments: intraperi-
toneal ImmunoRNase, dissolved in phosphate-buffered saline, was
administered at doses of 1.5mgkg
1 of body weight for six times
at 72-h intervals; and intraperitoneal trastuzumab, 3.75mgkg
1
and Erb-hcAb 2.5mgkg
1 were administered twice a week for
3 weeks. Tumour volume was measured using the formula
p/6larger diameter(smaller diameter)
2, as previously reported
(Ciardiello et al, 1996). Two mice from each group were killed on
day 25 to perform biochemical analysis.
RESULTS
Effects of EDIA on human breast cancer cells sensitive or
resistant to trastuzumab
We measured the expression of ErbB2 on breast cancer cell lines
JIMT-1 and KPL-4 (Kurebayashi et al, 1999; Tanner et al, 2004),
directly derived from patients with aggressive trastuzumab-
resistant tumours, and on MDA-MB-361 cells that are sensitive
to trastuzumab. A western blot analysis with an anti-ErbB2
monoclonal antibody was performed on lysates from the afore-
mentioned cancer cell lines. As shown in Figure 1, all cancer cell
lines express, at different levels, the ErbB2 receptor.
To test the anti-proliferative effects of anti-ErbB2 immunoa-
gents on cancer cell growth, we treated these cells in soft agar with
different doses of immunoagents. As shown in Figure 2, both Erb-
hRNase and Erb-hcAb caused a dose-dependent inhibition of
colony formation in all cancer cells tested, proving to be effective
also in trastuzumab-resistant JIMT-1 and KPL-4 cells, with an IC50
(concentration producing an inhibition of 50%) value of B50 and
100nM, respectively. No growth inhibition or very limited
inhibition (o20% for JIMT1 cells) was observed, as expected
(Tanner et al, 2004), when trastuzumab was tested in parallel
experiments carried out under identical conditions.
We also performed a cell-survival assay and observed that anti-
ErbB2 immunoagents caused a potent effect on the survival of
JIMT-1 (Figure 3A) and KPL-4 (Figure 3B) cells. As expected,
trastuzumab was ineffective on cell survival, whereas Erb-hRNase
and Erb-hcAb induced a 50% cell-survival inhibition in JIMT-1
and KPL-4 cells at a dose of 50nM for both immunoagents.
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sWe evaluated by western blot analysis the effects of treatment
with Erb-hRNase and Erb-hcAb on the expression of proteins
involved in the ErbB2 pathway in JIMT-1 and KPL-4 cells. As
shown in Figure 3C, Erb-hcAb and Erb-hRNase inhibited the
phosphorylation of MAPK and Akt more effectively than did
trastuzumab, thus suggesting that, unlike trastuzumab, EDIAs
retain their ability to inhibit the ErbB2 survival pathway in
trastuzumab-resistant cells.
In vivo anti-tumour effects of EDIA on trastuzumab-
resistant breast cancer cells grown in nude mice
In a first study, we xenografted BalbC nude mice with JIMT-1 and
KPL-4 tumours and treated the animals with trastuzumab and
Erb-hRNase (Figure 4). After 7 days, when tumours were clearly
detectable, mice were treated. Treatment with trastuzumab and
Erb-hRNase showed a similar effect on tumour growth, producing
about 70 and 50% tumour growth inhibition in JIMT-1 and
KPL-4 tumour models, respectively, at the end of the experiment
(Figures 4A and B).
In two different experiments, BalbC nude mice were xenografted
with the same tumour cells and treated with Erb-hcAb. In the first
experiment, when tumours were detectable, mice were treated with
3.3mgkg
1 of Erb-hcAb once a week by systemic administrations.
To directly compare the anti-tumour efficacy of this novel
immunoagent with that of trastuzumab, in parallel experiments,
the effects of equimolar doses (5mgkg
1) of trastuzumab were
tested on the same experimental models, as previously reported
(Tanner et al, 2004). Tumour volume was measured weekly until
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Figure 2 Effects of trastuzumab, ERB-hRNase and ERB-hcAb on the soft agar growth of MDA-MB-361, JIMT-1 and KPL-4 cells. Cells were treated with
the indicated concentrations of trastuzumab, Erb-hRNase and Erb-hcAb each day for three consecutive days. Colonies were counted after 10–14 days.
Results for each treatment are presented relative to untreated control cells. *Two-sided Po0.0001 vs control and vs negative control. Bars, s.d.
JIMT-1
MDA-MB-361
ErbB2
Actin
KPL-4
Figure 1 ErbB2 expression on human breast cancer cell lines. Western
blot analysis of ErbB2 protein expression on total cell lysates from KPL-4,
JIMT-1 and MDA-MB-361cells.
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sthe end of the experiments. We found that Erb-hcAb inhibited the
growth of tumours during the course of treatment, and its effects
were significantly more potent than that of trastuzumab (75 vs 30%
growth inhibition; P-value 0.033).
In the second experiment, treatment was performed on larger-
sized tumours with two doses at 72-h intervals of trastuzumab
(3.75mgkg
1) or Erb-hcAb (2.5mgkg
1). On day 56, 8 weeks after
tumour injection, all untreated mice bearing JIMT-1 and KPL-4
tumours reached the maximum allowed tumour size of about
2cm
3. On day 49, 3 weeks after treatment withdrawal, Erb-hcAb
produced about 50 and 65% tumour growth inhibition in JIMT-1
and KPL-4 tumour models, respectively (Figures 5A and B),
whereas trastuzumab produced about 75 and 65% tumour growth
inhibition in JIMT-1 and KPL-4 tumour models, respectively
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Figure 3 Effects of trastuzumab, Erb-hRNase and Erb-hcAb on survival (A and B) and signal transduction (C and D) of JIMT-1 and KPL-4 cells. (A and B)
5000 cells per well were plated in 96-well tissue culture plates for 48h in the presence of 7.5% serum, then deprived of serum for the following 24h and
finally treated with trastuzumab, Erb-hRNase or Erb-hcAb (50–200nM) in 0.1% serum for 72h. Cell counts were performed using trypan blue. Results for
each treatment are presented relative to that of untreated control cells. *Two-sided Po0.0001 vs control and vs negative control. Bars, s.d. (C and D)
Western blot analysis of protein expression in JIMT-1 and KPL-4 cells treated for 24h with trastuzumab (150nM), Erb-hRNase (50nM) and Erb-hcAb
(100nM) before protein extraction. For each immunoagent, the minimum concentration that gave clear effects was chosen.
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Figure 4 Effect of Erb-hRNase and trastuzumab on tumour growth of JIMT-1 (A) and KPL-4 (B) xenografts. On day 7, when tumours were clearly
detectable, mice were randomised (10 per group) to receive the following treatments: intraperitoneal (i.p.) trastuzumab (3.75mgkg
1 twice a week for 3
weeks) or i.p. ERB-hRNase (1.5mgkg
1, at 72-h intervals for 3 weeks). Control animals were treated with sterile phosphate-buffered saline solution.
Student’s t-test was used to compare tumour sizes among different treatment groups. Bars, s.d.; P-value 0.027.
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s(Figures 5A and B). These data on trastuzumab activity are
consistent with those of a previous study showing that trastuzu-
mab is able to inhibit the outgrowth of macroscopically detectable
JIMT-1 xenografted tumours, despite the in vitro intrinsic
resistance of JIMT1 cells to trastuzumab. The different response
of these cells in vitro and in vivo may not be surprising, as it can be
attributed to the well-documented ADCC of this agent (Barok et al,
2007, 2008).
These findings reflect the central role of the immune system in
mediating the effects of trastuzumab in vivo. If the clinical effects
of trastuzumab on tumour masses are mainly derived from ADCC,
which could lose its efficacy as the tumour grows, it is possible that
clinical benefits may decrease during extended follow-up and
would thus benefit from combinatorial use of Erb-hcAb, on the
basis of a different mechanism of action.
EDIAs inhibit the expression of signalling proteins in
KPL-4 and JIMT-1 xenografts
We analysed the effects of treatment on the expression of several
proteins having a critical role in cancer cell proliferation and
angiogenesis. Western blotting analysis was performed on cell lysates
from tumours removed at the end of the third week of treatment, on
day 25. As shown in Figure 6, both in JIMT-1 and KPL-4 tumour
xenografts, Erb-hcAb inhibited the phosphorylation/activation of
EGFR, Akt and MAPK, which are involved in ErbB2 signalling
cascade as shown in Figure 7. Conversely, trastuzumab did not affect
at all, and only slightly reduced the level of these proteins in KPL-4
and JIMT-1 cells, respectively. Furthermore, Erb-hcAb reduced the
expressions of ErbB2 and vascular endothelial growth factor in
treated cells as compared with untreated tumours. On the contrary,
trastuzumab did not affect the level of ErbB2, differently from
previous reports on sensitive mammary tumours (Petit et al, 1997;
Sliwkowski et al, 1999).
DISCUSSION
Although trastuzumab has been successfully used in patients with
ErbB2-overexpressing metastatic breast cancer, the objective
response rate to trastuzumab monotherapy is 12–34% for a
median duration of 9 months, when most patients become
resistant to treatment (Cobleigh et al, 1999).
Primary or acquired resistance is such a frequent problem that it
ultimately culminates in treatment failure. Thus, overcoming
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Figure 5 Effect of Erb-hcAb and trastuzumab on tumour growth of JIMT-1 (A) and KPL-4 (B) xenografts. On day 7, when tumours were clearly
detectable, mice were randomised (10 per group) to receive the following treatments: intraperitoneal (i.p.) trastuzumab (3.75mgkg
1, twice a week for 3
weeks) or i.p. Erb-hcAb (2.5mgkg
1, twice a week for 3 weeks). Control animals were treated with sterile phosphate-buffered saline solution. Student’s
t-test was used to compare tumour sizes among different treatment groups. Bars, s.d.
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Figure 6 Effect of Erb-hcAb and trastuzumab on signal transduction in
JIMT-1 and KPL-4 tumour xenografts. Western blotting was performed on
total lysates from tumour specimens of two mice killed on day 25 and
treated as in Figure 5.
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strastuzumab resistance represents an important challenge in the
improvement of immunotherapy outcomes.
The mechanisms underlying the acquisition of trastuzumab
resistance are not yet well defined, but pre-clinical studies have
indicated several molecular mechanisms that could contribute to
the development of trastuzumab resistance (Nahta and Esteva,
2006). Increased signalling through the PI3-K/Akt pathway could
induce the activation of multiple receptor pathways that include
ErbB-related receptors or non-ErbB receptors such as IGF1-R,
which seems to be involved in a cross-talk with ErbB2 in resistant
cells (Lu et al, 2001).
It has also been proposed that trastuzumab resistance may be
associated with decreased p27(kip1) levels (Nahta et al, 2004), or
with the loss of function of the tumour-suppressor PTEN gene, the
negative regulator of Akt, which results in strengthened Akt
signalling, which in turn leads to decreased sensitivity to
trastuzumab (Fujita et al, 2006).
Other evidence suggests that ErbB2-positive cells may develop
trastuzumab resistance by masking the epitope recognised by this
antibody. Recent studies have shown that a decreased interaction
between trastuzumab and ErbB2 is due to steric hindrance of
ErbB2 by cell surface proteins such as MUC4. An example is the
JIMT-1 cell line, established from the pleural effusion of a
trastuzumab-resistant breast cancer patient, in which the mem-
brane-proximal trastuzumab epitope is masked (Nagy et al, 2005).
The role of the epitope recognised by anti-ErbB2 antibodies is
further highlighted by the preservation of the binding efficiency of
an antibody such as 2C4, which recognises a membrane-distant
epitope in the extracellular part of ErbB2 (Nagy et al, 2005).
Other results indicate that lack of accessibility of the epitope
recognised by trastuzumab may limit the activity of this antibody
in vivo: only about half of ErbB2 amplification cases confirmed by
fluorescent in situ hybridisation (FISH) was found to be positive to
trastuzumab staining. Interestingly, the efficacy of trastuzumab-
based therapy was significantly higher in patients whose tumours
stained positively for trastuzumab, despite all tumours being FISH
positive (Bussolati et al, 2005). However, no cases of structural
modifications or altered expression levels of ErbB2 in resistant cell
lines have been reported.
On the basis of these considerations and the observations
reported above, we assumed that cells that become resistant to
trastuzumab could still be sensitive to treatment with antibodies
recognising different epitopes or interfering with different
intracellular signalling.
In this study, we found indeed that EDIAs are active on
trastuzumab-resistant cells, inhibiting the expression of proteins
involved in progression, survival and metastatic processes also. We
observed that trastuzumab inhibited tumour growth in vivo, most
likely because of ADCC, as previously reported (Barok et al, 2007),
but we also showed that trastuzumab did not inhibit the expression
of signalling protein, whereas Erb-hcAb and Erb-hRNase were able
to inhibit not only tumour growth but also signal transducers. We
believe that the sensitivity of trastuzumab-resistant cancer cells to
EDIA is likely due to the different epitope recognised by EDIA.
Recent investigations on the mechanism of anti-tumour action
of these anti-ErbB2 immunoagents have indicated that Erb-hcAb
induces the homodimerisation of ErbB2, which leads to its
downregulation and lysosomal degradation, and induces ADCC
(De Lorenzo et al, 2005); the anti-tumour action of ERB-hRNase
instead depends on its ribonuclease activity, which is exerted in the
cytosol (De Lorenzo et al, 2007b). Thus, it may not be surprising
that both immunoagents show similar cytotoxic effects, as Erb-
hcAb lacks the toxic RNase payload of Erb-hRNase, but in turn the
latter does not possess the Fc domain responsible for ADCC, and
contains a monovalent scFv that could not significantly interfere
with receptor dimerisation and degradation.
Moreover, a recent study showed that, unlike trastuzumab,
EDIAs do not show cardiotoxicity (Riccio et al, 2009). In this
study, Erb-hRNase and Erb-hcAb did not show toxic effects both
in vitro on rat cardiomyocytes and in vivo on a mouse model,
whereas trastuzumab was strongly toxic, thus suggesting that EDIA
could be safely used for therapeutic applications.
Altogether, these results suggest that EDIA could fulfil the
therapeutic need of patients ineligible for trastuzumab treatment
because of cardiac dysfunction, and could prove to be effective for
treatment of some breast cancer patients resistant to trastuzumab,
providing a strong rationale for a clinical translation in breast
cancer patients.
ACKNOWLEDGEMENTS
The authors thank Professor J Kurebayashi (Kawasaki Medical
School, Kurashiki, Japan) and Professor J Isola (Institute of
Medical Technology, University and University Hospital of
Tampere, 33520 Tampere, Finland) for providing KPL-4 and
JIMT-1 cells, respectively. This work was financially supported by
AIRC (Associazione Italian a per la Ricerca sul Cancro), Italy;
MUR (Ministero dell’Universita ` e della Ricerca), Italy; and
Biotecnol, SA, Portugal. Vincenzo Damiano is supported by a
fellowship from AIRC.
REFERENCES
Barok M, Bala ´zs M, Nagy P, Ra ´kosy Z, Treszl A, To ´th E, Juha ´sz I,
Park JW, Isola J, Vereb G, Szo ¨llosi J (2008) Trastuzumab
decreases the number of circulating and disseminated tumor cells
despite trastuzumab resistance of the primary tumor. Cancer Lett 260:
198–208
Barok M, Isola J, Pa ´lyi-Krekk Z, Nagy P, Juha ´sz I, Vereb G, Kauraniemi P,
Kapanen A, Tanner M, Vereb G, Szo ¨llo ¨si J (2007) Trastuzumab causes
antibody-dependent cellular cytotoxicity-mediated growth inhibition
of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic
drug resistance. Mol Cancer Ther 6: 2065–2072
Trastuzumab,
Erb-hcAb
ErbB2
MAPK
RAS RAF
SOS
GRB2
PI3-K
STAT
AKT PTEN
Gene transcription
PKC
NFKB
Survival
EGFR, ErbB3, ErbB4
MEK
Figure 7 Downstream effectors of the ErbB receptor signalling pathway.
AKT, protein kinase B; MAPK, mitogen-activated protein kinase; MEK,
MAPK/extracellular signal-related kinase; NF-kB, nuclear factor kB; PKC,
protein kinase C; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatidyl-
inositol-3,4,5-trisphosphate-3-phosphatase; STAT, signal transducer and
activator of transcription.
Effects of immunoagents on trastuzumab-resistant cells
T Gelardi et al
518
British Journal of Cancer (2010) 102(3), 513–519 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sBaselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal
antibodies. Ann Oncol 12: S35–S41
Bussolati G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A
(2005) A modified trastuzumab antibody for the immunohistochemical
detection of HER-2 overexpression in breast cancer. Br J Cancer 92:
1261–1267
Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D,
De Vita F, De Placido S, Bianco AR, Tortora G (2004) Antitumor activity
of ZD6474, a VEGFR tyrosine kinase inhibitor, in human cancer
cells with acquired resistance to anti-EGFR therapy. Clin Cancer Res
10: 784–793
Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M,
De Placido S, Mendelsohn J, Bianco AR, Tortora G (1996) Antitumor
activity of combined blockade of epidermal growth factor receptor and
protein kinase A. J Natl Cancer Inst 8: 1770–1776
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc
receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:
443–446
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L,
Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999)
Multinational study of the efficacy and safety of humanized anti-HER2
monoclonal antibody in women who have HER-2 overexpressing
metastatic breast cancer that has progressed after chemotherapy for
metastatic disease. J Clin Oncol 17: 2639–2648
De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R,
D’Alessio G (2004a) A fully human antitumor immunoRNase selective
for ErbB-2-positive carcinomas. Cancer Res 64: 4870–4874
De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D’Alessio G
(2005) Biological properties of a human compact anti-ErbB2 antibody.
Carcinogenesis 26: 1890–1895
De Lorenzo C, Di Malta C, Cali G, Troise F, Nitsch L, D’Alessio G (2007b)
Intracellular route and mechanism of action of ERB-hRNase, a human
anti-ErbB2 anticancer immunoagent. FEBS Lett 581: 296–300
De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D’Alessio G (2002) A new
human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8:
1710–1719
De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R,
D’Alessio G (2004b) A human, compact, fully functional anti-ErbB2
antibody as a novel antitumour agent. Br J Cancer 91: 1200–1204
De Lorenzo C, Troise F, Cafaro V, D’Alessio G (2007a) Combinatorial
experimental protocols for Erbicin-derived immunoagents and Hercep-
tin. Br J Cancer 97: 1354–1360
Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K,
Tsukuda K, Ogasawara Y, Shimizu N (2006) PTEN activity could be a
predictive marker of trastuzumab efficacy in the treatment of ErbB2-
overexpressing breast cancer. Br J Cancer 94: 247–252
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology:
herceptin acts as an anti-angiogenic cocktail. Nature 416: 279–280
Kim JY, Sun Q, Oglesbee M, Yoon SO (2003) The role of ErbB2 signaling in
the onset of terminal differentiation of oligodendrocytes in vivo.
J Neurosci 23: 5561–5571
Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K,
Mochizuki M, Nakamura H, Sonoo H (1999) Isolation and characteriza-
tion of a new human breast cancer cell line, KPL-4, expressing the ErbB
family receptors and interleukin-6. Br J Cancer 79: 707–717
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth
factor-I receptor signaling and resistance to trastuzumab (Herceptin).
J Natl Cancer Inst 93: 1852–1857
Nagy P, Friedla ¨nder E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin
TM (2005) Decreased accessibility and lack of activation of ErbB2 in
JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Cancer Res 65: 473–482
Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance.
Cancer Lett 232: 123–138
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ (2004) P27(kip1)
down-regulation is associated with trastuzumab resistance in breast
cancer cells. Cancer Res 64: 3981–3986
Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS
(1997) Neutralizing antibodies against epidermal growth factor and
ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial
growth factor production by tumor cells in vitro and in vivo: angiogenic
implications for signal transduction therapy of solid tumors. Am J Pathol
151: 1523–1530
Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M,
Laccetti P, Hrelia S, D’Alessio G, De Lorenzo C (2009) Cardiotoxic effects,
or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23: 3171–3178
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med 344:
783–792
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA
(1999) Nonclinical studies addressing the mechanism of action of
trastuzumab (Herceptin). Semin Oncol 26: 60–70
Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K,
Isola J (2004) Characterization of a novel cell line established
from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther
3: 1585–1592
Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism
of action, resistance and future perspectives in HER2-overexpressing
breast cancer. Ann Oncol 18: 977–984
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L,
Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ,
Press M (2002) Efficacy and safety of trastuzumab as a single agent in
first-line treatment of HER2-overexpressing metastatic breast cancer.
J Clin Oncol 20: 719–726
Effects of immunoagents on trastuzumab-resistant cells
T Gelardi et al
519
British Journal of Cancer (2010) 102(3), 513–519 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s